New ‘world-first’ Malaria vaccine in the pipeline

Australian researchers have potentially created a ‘world-first’ malaria vaccine that could save millions of lives. According to Queensland Australian of the Year 2010, Professor Michael Good, of Griffith University, his team have found a way to completely protect mice against multiple strains of malaria. The team hopes to begin human trials over the next year to see if it produces a similar response.

Professor Good said he was confident it would work in humans and provide near full protection against the blood-borne disease that kills about 1 million people each year. Malaria is caused by a parasite that is passed through the bite of infected mosquitoes.

malaria life cycleGood explained that a totally protective vaccine would be a huge breakthrough because the leading vaccine being trialled in Africa, RTS,S, provides only 30 to 50 per cent protection for a few months. He said other scientists had been able to protect mice against a single strain of the disease, but not multiple strains.

Called PlasProtecT, the vaccine will be unveiled at Friday's opening of Griffith University's Institute for Glycomics' Laboratory of Vaccines for the Developing World. PlasProtecT involved treating whole malaria parasites with a chemical treatment that puts them to sleep. When mice were given a dose of these sleeping parasites, it stimulated an immune response that protected them against the disease. Professor Good explained, “The vaccinated mice behave like nothing's happened to them. They get a very, very low number of parasites in their blood which rapidly clear over a period of a week or so and then they are fine.”

Professor Good added that if trials of the vaccine went well, it could be produced as a single injection in Queensland within five to 10 years. “If successful, we'll be able to make many many doses of the vaccine in our facilities up here at Griffith University. It doesn't require much technology, which means the vaccine would be very cheap to produce, which is good for poor countries,” he said.

Prof Good's team includes 13 post-doctoral researchers, assistants and students working in collaboration with a team of Australian and international researchers.

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2022, December 29). New ‘world-first’ Malaria vaccine in the pipeline. News-Medical. Retrieved on November 26, 2024 from https://www.news-medical.net/news/20110712/New-world-first-Malaria-vaccine-in-the-pipeline.aspx.

  • MLA

    Mandal, Ananya. "New ‘world-first’ Malaria vaccine in the pipeline". News-Medical. 26 November 2024. <https://www.news-medical.net/news/20110712/New-world-first-Malaria-vaccine-in-the-pipeline.aspx>.

  • Chicago

    Mandal, Ananya. "New ‘world-first’ Malaria vaccine in the pipeline". News-Medical. https://www.news-medical.net/news/20110712/New-world-first-Malaria-vaccine-in-the-pipeline.aspx. (accessed November 26, 2024).

  • Harvard

    Mandal, Ananya. 2022. New ‘world-first’ Malaria vaccine in the pipeline. News-Medical, viewed 26 November 2024, https://www.news-medical.net/news/20110712/New-world-first-Malaria-vaccine-in-the-pipeline.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Argonne receives $21.7 million to advance cancer and vaccine discoveries